A Phase 2 Trial to Evaluate Nafamostat in COVID-19 Patients
Latest Information Update: 13 May 2021
At a glance
- Drugs Nafamostat (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Ensysce Biosciences
- 07 May 2021 According to Ensysce Biosciences media release, this trial is expected to launch during the second half of 2021.
- 06 Oct 2020 New trial record